The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Li Zhang,Meenal Sinha,Sumit K. Subudhi,Brandon Chen,Jaqueline Marquez,E Liu,Kathryn Allaire,Alexander Cheung,Sharon Ng,Christopher Nguyen,Terence W. Friedlander,Rahul Aggarwal,Matthew H. Spitzer,James P. Allison,Eric J. Small,Padmanee Sharma,Lawrence Fong

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

2021

Li Zhang
Meenal Sinha
Sumit K. Subudhi
Brandon Chen
Jaqueline Marquez
E Liu
Kathryn Allaire
Alexander Cheung
Sharon Ng
Christopher Nguyen
Terence W. Friedlander
Rahul Aggarwal
Matthew H. Spitzer
James P. Allison
Eric J. Small
Padmanee Sharma
Lawrence Fong

5045Background: SipT is an FDA-approved autologous cellular immunotherapy targeting Prostatic Acid Phosphatase (PAP) that improves survival in patients with mCRPC. Combining immunotherapies could p...

Keywords:

Medicine
castration resistant
Prior Radiation Therapy
Ipilimumab
Internal medicine
Oncology
Sipuleucel-T
in patient
Prostate cancer
Autologous Cellular Immunotherapy
Prostatic acid phosphatase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations